Biotech | January 04, 2022
USFDA grants ILiAD Biotechnologies Fast Track Designation for pertussis vaccine
BPZE1 is the most advanced next-generation pertussis vaccine currently in clinical development
BPZE1 is the most advanced next-generation pertussis vaccine currently in clinical development
The first pilot study from India analyzing Covaxin-Covishield mixed doses
Emergency Use Authorisation application request to be submitted following one month required by FDA EUA guidance
Celltrion plans to provide dual treatment options for COVID-19; Regkirona for hospitalised patients and a nebulised cocktail therapy (CT-P63 in combination with Regkirona) for at- home settings
It plans to deliver over 300 million doses to the Indian government
The Covid-19 At-Home Test uses a simple nasal swab sample to enable individuals to self-test at home and receive accurate, reliable and quick results in as few as 20 minutes for SARS-CoV-2 and all known variants of concern, including Omicron
Alzheimer's disease is a serious, progressive and devastating disease with few treatment options
First Emergency Use Listing granted by WHO for a protein-based Covid-19 vaccine
Authorized booster increases Omicron neutralizing antibody levels approximately 37-fold
The study was performed independently by investigators at the US Food and Drug Administration (FDA), Center for Biologics Evaluation and Research
Subscribe To Our Newsletter & Stay Updated
